Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo

NeuroReport

Volumn 15, Issue 15, 2004, Pages 2375-2379

  Lastres Becker, Isabel ^a,c   Bizat, Nicolas ^b   Boyer, Frédéric ^b   Hantraye, Philippe ^b   Fernández Ruiz, Javier ^a   Brouillet, Emmanuel ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CNRS   (France)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

3 nitropropionic acid; Basal ganglia; Cannabinoids; Cb1; Huntington's disease; Neurodegeneration; Neuroprotection; Receptors

Indexed keywords

3 NITROPROPIONIC ACID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEGENERATION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DRUG TARGETING; HUNTINGTON CHOREA; IN VIVO STUDY; MALE; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; SIGNAL TRANSDUCTION;

ANIMALS; AUTORADIOGRAPHY; CONVULSANTS; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; GAMMA-AMINOBUTYRIC ACID; IN SITU HYBRIDIZATION; MALE; NITRO COMPOUNDS; PROPIONIC ACIDS; PSYCHOTROPIC DRUGS; RATS; RATS, INBRED LEW; RECEPTOR, CANNABINOID, CB1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STRIATONIGRAL DEGENERATION; SUCCINATE DEHYDROGENASE; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 8444239705     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200410250-00015     Document Type: Article

References (25)

1. Berardelli A, Noth J, Thompson PD, Bollen EL, Curra A, Deuschl G et al. Pathophysiology of chorea and bradykinesia in Huntington's disease. Moo Disord 1999; 14:398-403.
2. Crossman AR. Functional anatomy of movement disorders. J Anal 2000; 196:519-525.
3. Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F and Sipion S. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci 2001; 24:182-188.
4. Grundy RI, Rabuffetti M and Beltramo M. Cannabinoids and neuroprotection. Mol Neurobiol 2001; 24:29-52.
5. Grundy RI. The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin Invest Drugs 2002; 11:1-10.
6. Mechoulam R, Panikashvili A and Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 2002; 8:58-61.
7. Fernández-Ruiz JJ, Lastres-Becker I, Cabranes A, González S and Ramos JA. Endocannabinoids and basal ganglia functionality. Prostaglandins Leukotrienes Essential Fatty Acids 2002; 66:263-273.
8. Lastres-Becker I, De Miguel R and Fernández-Ruiz JJ. The endocannabinoid system and Huntington's disease. Curr Drug Target CNS Neurol Disord 2003; 2:335-347.
9. Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Brouillet E and Fernández-Ruiz J. Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate. Neuroreport 2003; 14:813-816.
10. Ouary S, Bizat N, Altairac S, Menetrat H, Mittoux V, Conde F et al. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies. Neuroscience 2000; 97:521-530.
11. Dautry C, Vauffrey F, Brouillet E, Bizat N, Condé F, Bloch G and Hantraye P. Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J Cerebr Blood Flow Metab 2000; 20:789-799.
12. Bizat N, Hermel JM, Boyer F, Jacquard C, Creminon C, Ouary S et al. Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. J Neurosci 2003; 23:5020-5030.
13. Blum D, Gall D, Galas MC, d'Alcantara P, Bantubungi K and Schiffmann SN. The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J Neurosci 2002; 22:9122-9133.
14. Paxinos G and Watson C. The Rat Brain in Stereotaxic Coordinates. London: Academic Press; 1986.
15. Herkenham M, Lynn AB, de Costa BR and Richfield EK. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 1991; 547:267-274.
16. 35S]thio]-triphosphate binding. Proc Natl Acad Sci USA 1995; 92: 7242-7246.
17. Rubino T, Massi P, Patrini G, Venier I, Giagnoni G and Parolaro D. Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybridization study. Neuroreport 1994; 5:2493-2496.
18. Lastres-Becker I, Hansen HH, Berrendero F, de Miguel R, Pérez-Rosado A, Manzanares J et al. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse 2002; 44:23-35.
19. Brouillet E, Guyot MC, Mittoux V, Altairac S, Condé F, Palfi S and Hantraye P. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J Neurochem 1998; 70:794-805.
20. Palkovits M and Brownstein J. Maps and Guide to Microdissection of the Rat Brain. Amsterdam: Elsevier; 1988.
21. Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V and Fernández-Ruiz JJ. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J Neurochem 2003; 84:1097-1109.
22. Brouillet E, Condé F, Beal MF and Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 1999; 59: 427-468.
23. Page KJ, Besret L, Jain M, Monaghan EM, Dunnett SB and Everitt BJ. Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia. Exp Brain Res 2000; 130:142-150.
24. Bizat N, Hermel JMH, Humbert S, Jacquard C, Créminon C, Escartin C et al. In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration: implication of a calpain-mediated cleavage of active caspase-3. J Biol Chem 2003; 278:43245-43253.
25. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter VVJ and Greenamyre JT. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nature Neurosci 2002; 5:731-736.